BRPI0821248A2 - Inibidores de cinesina como fármacos terapêuticos para câncer - Google Patents

Inibidores de cinesina como fármacos terapêuticos para câncer

Info

Publication number
BRPI0821248A2
BRPI0821248A2 BRPI0821248-1A BRPI0821248A BRPI0821248A2 BR PI0821248 A2 BRPI0821248 A2 BR PI0821248A2 BR PI0821248 A BRPI0821248 A BR PI0821248A BR PI0821248 A2 BRPI0821248 A2 BR PI0821248A2
Authority
BR
Brazil
Prior art keywords
cancer drugs
therapeutic cancer
kinesin inhibitors
kinesin
inhibitors
Prior art date
Application number
BRPI0821248-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821248(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0821248A2 publication Critical patent/BRPI0821248A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0821248-1A 2007-12-14 2008-12-12 Inibidores de cinesina como fármacos terapêuticos para câncer BRPI0821248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Publications (1)

Publication Number Publication Date
BRPI0821248A2 true BRPI0821248A2 (pt) 2015-06-16

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821248-1A BRPI0821248A2 (pt) 2007-12-14 2008-12-12 Inibidores de cinesina como fármacos terapêuticos para câncer

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552510A (en) * 2004-06-18 2010-12-24 Novartis Vaccines & Diagnostic N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).

Also Published As

Publication number Publication date
US8252832B2 (en) 2012-08-28
EA201000900A1 (ru) 2011-02-28
TW200930704A (en) 2009-07-16
EP2229170B1 (en) 2014-01-22
CL2008003707A1 (es) 2009-06-05
UY31532A1 (es) 2009-08-03
KR20100098394A (ko) 2010-09-06
PE20091451A1 (es) 2009-10-19
PA8807801A1 (es) 2009-07-23
CA2708822A1 (en) 2009-06-25
WO2009077448A1 (en) 2009-06-25
CR11412A (es) 2010-06-30
EP2229170A1 (en) 2010-09-22
JP5501976B2 (ja) 2014-05-28
NI201000091A (es) 2011-03-15
GT201000172A (es) 2012-04-30
SMAP201000095A (it) 2010-09-10
CN101939005A (zh) 2011-01-05
US20090239922A1 (en) 2009-09-24
ECSP10010248A (es) 2010-07-30
CN101939005B (zh) 2015-12-16
US20130012560A1 (en) 2013-01-10
JP2011506402A (ja) 2011-03-03
ES2459442T3 (es) 2014-05-09
TN2010000204A1 (en) 2011-11-11
MA31872B1 (fr) 2010-11-01
DOP2010000175A (es) 2010-06-30
IL205831A0 (en) 2010-11-30
AU2008337570B2 (en) 2012-04-05
CO6290651A2 (es) 2011-06-20
SMP201000095B (it) 2011-09-09
AU2008337570A1 (en) 2009-06-25
EA018014B1 (ru) 2013-04-30
MY150214A (en) 2013-12-13
US8664256B2 (en) 2014-03-04
AR069676A1 (es) 2010-02-10
NZ585142A (en) 2012-03-30
GEP20125647B (en) 2012-09-25

Similar Documents

Publication Publication Date Title
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
LT3192529T (lt) Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
DK2121139T3 (da) Formulations for cancer treatment
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0808191A2 (pt) dispositivos implantáveis híbridos terapêuticos
BRPI0821316A2 (pt) Adaptador antioclusão para cateter
EP2127671A4 (en) THERAPEUTIC CANCER
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0813670A2 (pt) Compostos para tratamento
DK2219683T3 (da) Målrettet radioterapi
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1008664A2 (pt) comprimidos para a terapia de combinação
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0810816A2 (pt) Medicamento e métodos para tratar doenças auto-imune e câncer
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0813789A2 (pt) Potenciação de quimioterapia contra câncer
BRPI0920743A2 (pt) ribonucleases terapeuticas
DK2437736T3 (da) Lægemiddelindgivelsessystemer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.